Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-Site, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of eRapa to Improve Clinical Outcomes in Patients With Familial Adenomatous Polyposis

NCT06950385 is registered in ClinicalTrials.gov with Rapamycin Holdings Inc. as lead sponsor.

NCT NCT06950385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06950385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-Site, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of eRapa to Improve Clinical Outcomes in Patients With Familial Adenomatous Polyposis
Lead sponsor
Rapamycin Holdings Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
July 18, 2025
Completion date
January 31, 2031
Enrollment
168 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

familial adenomatous polyposis (fap)